Asia Pacific Leukemia Therapeutics market has been estimated at USD 1.63 Billion in 2022 and is projected to reach USD 2.78 Billion by 2027, at a CAGR of 11.2% during the forecast period from 2022 to 2027.
Leukemia is the cancer of the white blood cells or the bone marrow, which occurs due to an abnormal increase in the count of white blood cells. There are several types of leukemia that appear suddenly and progress rapidly over days to weeks. It can be identified by the spread of the diseases and by the type of the blood cell that is affected.
The market for Leukemia Therapeutics in Asia-Pacific region is mainly driven due to factors like increasing aging population due to which there is an increasing occurrence of leukemia, along with increasing awareness of patients regarding most recent technological developments.
But, the market growth is feared to drop due to the high costs of drugs and therapies.
This research report on the APAC Leukemia Therapeutics Market has been segmented and sub-segmented into the following categories
By Disease Condition:
By Diagnosis:
By Treatments:
By Drugs:
By Country:
By disease condition, chronic myeloid leukemia dominated the overall therapeutic market owing to the high prevalence rate. Stem cell therapy and bone marrow transplant are the emerging trends in the leukemia therapeutics market. Gleevec was one of the major market growth contributors, in the drugs category.
The Asia-pacific market is growing at a very high rate, due to the rising consumer market, favorable government support for enhanced healthcare infrastructure, and raising awareness for healthcare among the population in developing nations of the region.
The Top companies leading in the APAC Leukemia Therapeutics market profiled in this report are Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb, Eisai Co. Ltd, Biogen Idec, ERYtech Pharma, Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Disease Condition
5.1.1 Chronic Lymphatic Leukemia
5.1.2 Acute Lymphatic Leukemia
5.1.3 Chronic Myeloid Leukemia
5.1.4 Acute Myeloid Leukemia
5.2 By Diagnosis
5.2.1 CT scan
5.2.2 Biopsy
5.2.3 MRI
5.3 By Treatments
5.3.1 Chemotherapy
5.3.2 Radiation therapy
5.3.3 Immunotherapy
5.3.4 Surgery
5.3.5 Targeted Therapy
5.3.6 Bone marrow transplant
5.3.7 Stem Cell Therapy
5.4 By Drugs
5.4.1 Gleevec
5.4.2 Sapacitabine
5.4.3 GA101
5.4.4 Vasaroxine
5.4.5 Tosedosat
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 F. Hoffmann-La Roche Ltd
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 GlaxoSmithKline Pharmaceuticals Limited
9.3 Novartis International AG
9.4 Bristol-Myers Squibb
9.5 Eisai Co. Ltd
9.6 Biogen Idec
9.7 ERYtech Pharma
9.8 Celgene Corporation
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Disease Condition
5.1.1 Chronic Lymphatic Leukemia
5.1.2 Acute Lymphatic Leukemia
5.1.3 Chronic Myeloid Leukemia
5.1.4 Acute Myeloid Leukemia
5.2 By Diagnosis
5.2.1 CT scan
5.2.2 Biopsy
5.2.3 MRI
5.3 By Treatments
5.3.1 Chemotherapy
5.3.2 Radiation therapy
5.3.3 Immunotherapy
5.3.4 Surgery
5.3.5 Targeted Therapy
5.3.6 Bone marrow transplant
5.3.7 Stem Cell Therapy
5.4 By Drugs
5.4.1 Gleevec
5.4.2 Sapacitabine
5.4.3 GA101
5.4.4 Vasaroxine
5.4.5 Tosedosat
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 F. Hoffmann-La Roche Ltd
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 GlaxoSmithKline Pharmaceuticals Limited
9.3 Novartis International AG
9.4 Bristol-Myers Squibb
9.5 Eisai Co. Ltd
9.6 Biogen Idec
9.7 ERYtech Pharma
9.8 Celgene Corporation
9.9 Genmab A/S
9.10 Cephalon Inc.
9.11 Clavis Pharma
9.12 Pfizer Inc.
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
9.9 Genmab A/S
9.10 Cephalon Inc.
9.11 Clavis Pharma
9.12 Pfizer Inc.
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
